Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma

BackgroundDeregulations of long non-coding RNAs (lncRNAs) have been implicated in cancer initiation and progression. Current methods can only capture differential expression of lncRNAs at the population level and ignore the heterogeneous expression of lncRNAs in individual patients.MethodsWe propose a method (LncRIndiv) to identify differentially expressed (DE) lncRNAs in individual cancer patients by exploiting the disrupted ordering of expression levels of lncRNAs in each disease sample in comparison with stable normal ordering. LncRIndiv was applied to lncRNA expression profiles of lung adenocarcinoma (LUAD). Based on the expression profile of LUAD individual-level DE lncRNAs, we used a forward selection procedure to identify prognostic signature for stage I-II LUAD patients without adjuvant therapy.ResultsIn both simulated data and real pair-wise cancer and normal sample data, LncRIndiv method showed good performance. Based on the individual-level DE lncRNAs, we developed a robust prognostic signature consisting of two lncRNA (C1orf132 and TMPO-AS1) for stage I-II LUAD patients without adjuvant therapy (P = 3.06 × 10−6, log-rank test), which was confirmed in two independent datasets of GSE50081 (P = 1.82 × 10−2, log-rank test) and GSE31210 (P = 7.43 × 10−4, log-rank test) after adjusting other clinical factors such as smoking status and stages. Pathway analysis showed that TMPO-AS1 and C1orf132 could affect the prognosis of LUAD patients through regulating cell cycle and cell adhesion.ConclusionsLncRIndiv can successfully detect DE lncRNAs in individuals and be applied to identify prognostic signature for LUAD patients.

[1]  Libin Chen,et al.  Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer , 2016, Briefings Bioinform..

[2]  G. Mills,et al.  Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. , 2015, Cancer cell.

[3]  Z. Zhao,et al.  Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine , 2016, Oncogenesis.

[4]  Ya‐Wen Cheng,et al.  MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc , 2015, Annals of Surgical Oncology.

[5]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Mengmeng Zhang,et al.  The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2 , 2014, Oncotarget.

[7]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[8]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[9]  Paul L. Roebuck,et al.  TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. , 2015, Cancer research.

[10]  Sheila M. Reynolds,et al.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.

[11]  Y. Lin,et al.  MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3 , 2015, Tumor Biology.

[12]  H. Lian.  MOST: detecting cancer differential gene expression. , 2007, Biostatistics.

[13]  J. Minna,et al.  miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer , 2013, Oncogene.

[14]  Gongchao Wang,et al.  The long noncoding RNA LINC01207 promotes proliferation of lung adenocarcinoma. , 2015, American journal of cancer research.

[15]  Xuelian Li,et al.  An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma , 2014, Journal of Translational Medicine.

[16]  Vikram Agarwal,et al.  Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression , 2016, Molecular cell.

[17]  D.,et al.  Regression Models and Life-Tables , 2022 .

[18]  Debora S. Marks,et al.  miRcode: a map of putative microRNA target sites in the long non-coding transcriptome , 2012, Bioinform..

[19]  Jian Zhang,et al.  A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells , 2014, Tumor Biology.

[20]  Baolin Wu,et al.  Cancer outlier differential gene expression detection. , 2007, Biostatistics.

[21]  Chi-Ying F. Huang,et al.  miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..

[22]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[23]  Maoni Guo,et al.  A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients , 2015, Scientific Reports.

[24]  Xiaoqin Zhang,et al.  A long non-coding RNA signature in glioblastoma multiforme predicts survival , 2013, Neurobiology of Disease.

[25]  Tatsuya Kato,et al.  Overexpression of CDC20 predicts poor prognosis in primary non‐small cell lung cancer patients , 2012, Journal of surgical oncology.

[26]  X. Gou,et al.  Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. , 2015, Archives of biochemistry and biophysics.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  Hao Cai,et al.  Individualized identification of disease-associated pathways with disrupted coordination of gene expression , 2016, Briefings Bioinform..

[29]  Xin Chen,et al.  miR‐372 Regulates Glioma Cell Proliferation and Invasion by Directly Targeting PHLPP2 , 2015, Journal of cellular biochemistry.

[30]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[31]  A. Sweet-Cordero,et al.  Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. , 2010, Cancer research.

[32]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.

[33]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[34]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[35]  Jing Zhu,et al.  GO-function: deriving biologically relevant functions from statistically significant functions , 2012, Briefings Bioinform..

[36]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[37]  Harvey Risch,et al.  Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer , 2015, Oncotarget.

[38]  R. Tibshirani,et al.  Outlier sums for differential gene expression analysis. , 2007, Biostatistics.

[39]  G. Pan,et al.  Enhanced expression of long non-coding RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[40]  Mengmeng Zhang,et al.  Autophagy‐related prognostic signature for breast cancer , 2016, Molecular carcinogenesis.

[41]  Debashis Ghosh,et al.  COPA - cancer outlier profile analysis , 2006, Bioinform..

[42]  Qiang Sun,et al.  Individual-level analysis of differential expression of genes and pathways for personalized medicine , 2015, Bioinform..